Study investigates the occurrence of ADAMTS13 antibodies in COVID-19 patients and their association with disease severity and lower ADAMTS13 activity. The findings suggest the need to include ADAMTS13 antibodies in diagnosing and managing SARS-CoV-2 infections.
Nuclera appoints Joseph Bertelsen as Chief Commercial Officer
Key appointment to lead global commercial launch of eProtein Discovery platform